MHC CLASS II-RESTRICTED TRANSGENIC T CELL RECEPTOR THERAPY TARGETING MUTANT CAPICUA TRANSCRIPTIONAL REPRESSOR IN EXPERIMENTAL GLIOMAS

被引：0
|
作者：
Kilian, M. [1 ,2 ]
Friedrich, M. [1 ,2 ]
Sanghvi, K. [1 ,2 ]
Green, E. [1 ,2 ]
Pusch, S. [3 ,4 ]
von Deimling, A. [3 ,4 ]
Wick, W. [5 ,6 ]
Sahm, F. [3 ,4 ]
Platten, M. [1 ,2 ]
Bunse, L. [1 ,2 ]
机构：
[1] German Canc Res Ctr, DKTK Clin Cooperat Unit Neuroimmunol & Brain Tum, Heidelberg, Germany
[2] Heidelberg Univ, Med Fac Mannheim, Dept Neurol, MCTN, Mannheim, Germany
[3] German Canc Res Ctr, DKTK Clin Cooperat Unit Neuropathol, Heidelberg, Germany
[4] Heidelberg Univ, Univ Heidelberg Hosp, Dept Neuropathol, Heidelberg, Germany
[5] Heidelberg Univ, Univ Heidelberg Hosp, Neurol Clin & Natl Ctr Tumor Dis, Heidelberg, Germany
[6] German Canc Res Ctr, DKTK Clin Cooperat Unit Neurooncol, Heidelberg, Germany
来源：
NEURO-ONCOLOGY | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OS12.4.A
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [1] T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
    Kilian, Michael
    Friedrich, Mirco
    Sanghvi, Khwab
    Green, Edward
    Pusch, Stefan
    Kawauchi, Daisuke
    Loewer, Martin
    Sonner, Jana K.
    Kraemer, Christopher
    Zaman, Julia
    Jung, Stefanie
    Breckwoldt, Michael O.
    Willimksy, Gerald
    Eichmueller, Stefan B.
    von Deimling, Andreas
    Wick, Wolfgang
    Sahm, Felix
    Platten, Michael
    Bunse, Lukas
    CLINICAL CANCER RESEARCH, 2022, 28 (02) : 378 - 389
  • [2] Vulnerability of allografts to rejection by MHC class II-restricted T-cell receptor transgenic mice
    Lee, MK
    Huang, XL
    Jarrett, BP
    Moore, DJ
    Desai, NM
    Lian, MM
    Markmann, JW
    Deng, SP
    Frank, A
    Singer, A
    Velidedeoglu, E
    Caton, AJ
    Markmann, JF
    TRANSPLANTATION, 2003, 75 (08) : 1415 - 1422
  • [3] Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor
    Deng, Lu
    Langley, Ries J.
    Brown, Patrick H.
    Xu, Gang
    Teng, Leslie
    Wang, Qian
    Gonzales, Monica I.
    Callender, Glenda G.
    Nishimura, Michael I.
    Topalian, Suzanne L.
    Mariuzza, Roy A.
    NATURE IMMUNOLOGY, 2007, 8 (04) : 398 - 408
  • [4] CHARACTERIZATION OF MHC CLASS II-RESTRICTED T-CELL RECEPTORS FOR T-CELL THERAPY OF HBV INFECTION
    Schreiber, S.
    Honz, M.
    Schiemann, M.
    Zielinski, C.
    Protzer, U.
    Wisskirchen, K.
    CYTOTHERAPY, 2019, 21 (05) : S10 - S10
  • [5] CHARACTERIZATION OF MHC CLASS II-RESTRICTED T-CELL RECEPTORS FOR T-CELL THERAPY OF HBV INFECTION
    Schreiber, S.
    Honz, M.
    Schiemann, M.
    Sette, A.
    Zielinski, C.
    Protzer, U.
    Wisskirchen, K.
    HUMAN GENE THERAPY, 2019, 30 (12) : A10 - A10
  • [6] Characterization of MHC Class II-Restricted T-Cell Receptors for T-Cell Therapy of HBV Infection
    Schreiber, Sophia
    Honz, Melanie
    Schiemann, Matthias
    Sette, Alessandro
    Zielinski, Christina
    Protzer, Ulrike
    Wisskirchen, Karin
    MOLECULAR THERAPY, 2020, 28 (04) : 520 - 520
  • [7] ARE MHC CLASS II-RESTRICTED CYTOTOXIC LYMPHOCYTES-T IMPORTANT
    BRAAKMAN, E
    ROTTEVEEL, FTM
    VANBLEEK, G
    VANSEVENTER, GA
    LUCAS, CJ
    IMMUNOLOGY TODAY, 1987, 8 (09): : 265 - 267
  • [8] Generation of an MHC class II-restricted T cell epitope by extracellular processing of hepatitis δ antigen
    Accapezzato, D
    Nisini, R
    Paroli, M
    Bruno, G
    Bonino, F
    Houghton, M
    Barnaba, V
    JOURNAL OF IMMUNOLOGY, 1998, 160 (11): : 5262 - 5266
  • [9] MHC CLASS II-RESTRICTED T-CELL-RECEPTORS PROVIDE HELP FOR T-CELL-THERAPY OF HEPATITIS B VIRUS INFECTION
    Schreiber, S.
    Wettengel, J.
    Krey, K.
    Wisskirchen, K.
    Protzer, U.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A31 - A31
  • [10] Enhancement of class II-restricted T cell responses by costimulatory NK receptors for class I MHC proteins
    MAndelboim, O
    Davis, DM
    Reyburn, HT
    ValesGomez, M
    Sheu, EG
    Pazmany, L
    Strominger, JL
    SCIENCE, 1996, 274 (5295) : 2097 - 2100
12345